I am torn in this … market …. by my (own) motivating quotes : Where there is chaos, there is oppurtunity or the old historical favorite; pick up your rifle and put on your helmet… A day off is due … but, all I see is more … work sorting out the issues …
Mid-Day: The NASDAQ is UP +15.12 (+0.59%) to 2,581.17. The Dow is DOWN -2.88 (-0.03%) to 11,430.04.
Mid-Day Movers: Aastrom (ASTM), BioMimetic (NASDAQ:BMTI), Dendreon (NASDAQ:DNDN), Geron (NASDAQ:GERN), ImmunoCellular (OTC BB: IMUC), International Stem Cell (OTC BB: ISCO), ReNeuron (RENE.LON), ThermoGenesis (NASDAQ:KOOL)
What’s new in the regenerative medicine/stem cell market …
ImmunoCellular (OTC BB IMUC) receives Notice of Allowance of Patent for key US Patent for Lead Product Candidate, ICT-107: OTCBB: IMUC received allowance of patent claims related to ICT-107, the dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM); titled “Cancer Vaccines and Vaccination Methods,” which covers the method of delivery and the composition of the six antigens in ICT-107 that include TRP-2, MAGE-1, HER-2,IL-13 receptor a2, gp100 and AIM-2. The notice of allowance for this patent provides support for intellectual property protection.
International Stem Cell’s Research Scientists Successfully Completed the First Series of Preclinical Animal Trials of Neuronal: OTCBB: ISCO completed of the first series of preclinical studies designed to support the safety and utility of neuronal cells derived from human parthenogenetic stem cell line (hpSC). The bottom line, these initial experiments, demonstrating that the derived neuronal cells were able to survive in mice brains without giving rise to tumors, represent a key milestone towards possible therapeutic applications including treating Parkinson’s disease.
ThermoGenesis acceptance of AXP® Submission by Regulatory Body in China: KOOL’s submission for approval of the AXP® AutoXpress® (NYSE:AXP) which is used to concentrate stem cells from cord blood, has been accepted by the State Food & Drug Administration(SFDA) in China. The bottom line, KOOL has established a strong footprint for its cord blood products in China through several major customer and distribution agreements. This represents the successful completion of product testing and the administrative acceptance of the submission. Final technical review is now in process prior to in-country registration approval and commercial sales of the system. This is an important step in the regulatory process and KOOL should receive regulatory approval for the AXP in China by early calendar 2012.